Improvement of the synthesis and pharmacokinetic properties of chromenotriazolopyrimidine MDM2-p53 protein-protein inhibitors

被引:35
|
作者
Beck, Hilary P. [1 ]
DeGraffenreid, Michael [1 ]
Fox, Brian [1 ]
Allen, John G. [2 ]
Rew, Yosup [1 ]
Schneider, Stephen [3 ]
Saiki, Anne Y. [4 ]
Yu, Dongyin [4 ]
Oliner, Jonathan D. [4 ]
Salyers, Kevin [5 ]
Ye, Qiuping [6 ]
Olson, Steven [1 ]
机构
[1] Amgen Inc, Chem Res & Discovery, San Francisco, CA 94080 USA
[2] Amgen Inc, Chem Res & Discovery, Thousand Oaks, CA 91320 USA
[3] Amgen Inc, Chem Res & Discovery, Cambridge, MA 02142 USA
[4] Amgen Inc, Oncol Res, Thousand Oaks, CA 91320 USA
[5] Amgen Inc, PKDM, Thousand Oaks, CA 91320 USA
[6] Amgen Inc, PKDM, San Francisco, CA 94080 USA
关键词
Oncology; Protein-protein interaction; Pharmacokinetics; SMALL-MOLECULE INHIBITORS; CANCER-THERAPY; P53; AMPLIFICATION; APOPTOSIS; STABILITY; BINDING;
D O I
10.1016/j.bmcl.2010.11.027
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Human murine double minute 2 (MDM2) is a negative regulator of p53, which plays an important role in cell cycle and apoptosis. We report several optimizations to the synthesis of the chromenotriazolopyrimidine series of MDM2-p53 protein-protein interaction inhibitors. Additionally, the in vitro and in vivo stability, pharmacokinetic properties and solubility were improved through N-substitution. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2752 / 2755
页数:4
相关论文
共 50 条
  • [41] A Fluorescent Probe for Imaging p53-MDM2 Protein-Protein Interaction
    Liu, Zhenzhen
    Miao, Zhenyuan
    Li, Jin
    Fang, Kun
    Zhuang, Chunlin
    Du, Lupei
    Sheng, Chunquan
    Li, Minyong
    CHEMICAL BIOLOGY & DRUG DESIGN, 2015, 85 (04) : 411 - 417
  • [42] DISRUPTION OF P53/MDM2/MDMX PROTEIN-PROTEIN INTERACTIONS
    Topper, M.
    Zhou, M.
    Anderson, L.
    McLaughlin, M.
    BIOPOLYMERS, 2009, 92 (04) : 332 - 332
  • [43] Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein–protein interaction
    Maxim Gureev
    Daria Novikova
    Tatyana Grigoreva
    Svetlana Vorona
    Alexander Garabadzhiu
    Vyacheslav Tribulovich
    Journal of Computer-Aided Molecular Design, 2020, 34 : 55 - 70
  • [44] Inhibition of the p53-MDM2 interaction:: Targeting a protein-protein interface
    Chène, P
    MOLECULAR CANCER RESEARCH, 2004, 2 (01) : 20 - 28
  • [45] Synthesis and cytotoxicity of novel dispiro derivatives of 5-arylidenoxazolones, potential inhibitors of p53-MDM2 protein-protein interaction
    Beloglazkina, A. A.
    Skvortsov, D. A.
    Tafeenko, V. A.
    Majouga, A. G.
    Zyk, N. V.
    Beloglazkina, E. K.
    RUSSIAN CHEMICAL BULLETIN, 2018, 67 (03) : 562 - 569
  • [46] Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives as Novel Inhibitors of p53-MDM2 Protein-Protein Interaction
    Zhuang, Chunlin
    Miao, Zhenyuan
    Zhu, Lingjian
    Dong, Guoqiang
    Guo, Zizhao
    Wang, Shengzheng
    Zhang, Yongqiang
    Wu, Yuelin
    Yao, Jianzhong
    Sheng, Chunquan
    Zhang, Wannian
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (22) : 9630 - 9642
  • [47] Synthesis and biological evaluation of thio-benzodiazepines as novel small molecule inhibitors of the p53-MDM2 protein-protein interaction
    Zhuang, Chunlin
    Miao, Zhenyuan
    Zhu, Lingjian
    Zhang, Yongqiang
    Guo, Zizhao
    Yao, Jianzhong
    Dong, Guoqiang
    Wang, Shengzheng
    Liu, Yang
    Chen, Hai
    Sheng, Chunquan
    Zhang, Wannian
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (11) : 5654 - 5661
  • [48] Proapoptotic modification of substituted isoindolinones as MDM2-p53 inhibitors
    Grigoreva, Tatyana A.
    Novikova, Daria S.
    Petukhov, Alexey V.
    Gureev, Maxim A.
    Garabadzhiu, Alexander V.
    Melino, Gerry
    Barlev, Nickolai A.
    Tribulovich, Vyacheslav G.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (23) : 5197 - 5202
  • [49] Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
    Thayer, Kelly M.
    Beyer, George A.
    PLOS ONE, 2016, 11 (03):
  • [50] Selective and potent morpholinone inhibitors of the MDM2-p53 interaction
    Gonzalez, Ana Z.
    Eksterowics, John
    Beck, Hilary P.
    Canon, Jude
    Chen, Ada
    Chow, David
    Duquette, Jason
    Fox, Brian M.
    Fu, Jiasheng
    Houze, Jonathan
    Jin, Lixia
    Li, Yihong
    Li, Zhihong
    Lo, Mei-Chu
    Long, Alexander M.
    McGee, Lawrence R.
    McIntosh, Joel
    Oliner, Jonathan D.
    Osgood, Tao
    Rew, Yosup
    Saiki, Anne Y.
    Shaffer, Paul
    Wortman, Sarah
    Yakowek, Peter
    Yan, Xuelei
    Ye, Qiuping
    Yu, Dongyin
    Zhao, Xiaoning
    Zhou, Jing
    Olson, Steven H.
    Medina, Julio C.
    Sun, Daqing
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246